ArticleMedicine2026
Association of high-sensitivity troponin with advanced fibrosis in metabolic dysfunction-associated steatotic liver disease and the potential mediating role of inflammation: A cross-sectional study of NHANES, 1999 to 2004.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the high prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe adverse hepatic outcomes, risk stratification for patients with MASLD is crucial. Notably, cardiovascular disease (CVD) represents the leading cause of mortality in this population. High-sensitivity troponin (hs-troponin) is a well-established biomarker of subclinical myocardial injury and predicts cardiovascular outcomes. However, its specific relationship with advanced liver fibrosis (ALF) in MASLD remains unexplored. Therefore, we investigated this association in individuals with MASLD without CVD. We analyzed data from 4684 adults aged ≥18 years in the 1999 to 2004 National Health and Nutrition Examination Survey. Multivariable logistic regression examined associations between hs-troponin and ALF. Diagnostic utility was assessed using receiver operating characteristic curve analysis. Moreover, we conducted a mediation analysis to explore the role of inflammation, as represented by the monocyte-to-lymphocyte ratio, in the aforementioned association. Among 4684 patients without CVD, 169 had ALF. After controlling for confounding factors, hs-troponin T showed a significant positive association with ALF (adjusted odds ratio: 1.02, 95% confidence interval: 1.01-1.03, P = .020). Additionally, receiver operating characteristic analysis indicated that at a cutoff of 7.28 ng/L, hs-troponin T predicted ALF with an area under the curve of 0.85 (95% confidence interval: 0.82-0.88). Further mediation analysis revealed that inflammation partially mediated the association between hs-troponin T and ALF. Our findings indicate that elevated hs-troponin T is independently associated with a higher risk of ALF, which can assist clinicians in risk stratification for this population. These findings suggest that hs-troponin T, a marker of subclinical cardiovascular stress, may also serve as a practical tool for hepatic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.